caa a22 4500 477108636 CHVBK 20180405111602.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF01411063 doi (NATIONALLICENCE)springer-10.1007/BF01411063 Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model [Elektronische Daten] [L. Wahlberg, P. Almqvist, M. Glantz, J. Boëthius] Summary: The purpose of this study was to fabricate and investigate amsacrine containing polymeric rods for use in interstitial chemotherapy of malignant glioma. Ethylene vinyl acetate copolymer (EVAc) rods containing 40% amsacrine (AMSA) were fabricated successfully with an extrusion method. In vitro kinetic studies revealed a high level of reproducibility of the production process. The release of AMSA showed a biphasic pattern consistent with a matrix-type controlled-release system with an initial more rapid release rate followed by a slower and more linear release phase. Release of AMSA was observed for over 6 months and the rods continue to release in a stable fashion. In vitro studies using rat glioma (RG2) in cell culture showed that cells treated with AMSA released from the rods were killed in a dose dependent manner indicating that AMSA incorporated into the polymer remained biologically active. In vivo studies of rats with single AMSA rods implanted five days after RG2 tumour implantation revealed histological evidence of an antitumour effect as well as an increased survival (p < 0.0003). The mean survival of the amsacrine treated rats was 78 days with 50% still remaining alive > 5 months after implantation. All control animals developed tumours and died within 15-19 days after tumour implantation (mean=17 days). Amsacrine implanted animals showed no significant histological or clinical evidence of toxicity. We conclude that amsacrine containing EVAc rods can be safely and efficaciously used against the RG2 experimental glioma in a rat model and warrant further investigation. Springer-Verlag, 1996 Controlled drug delivery nationallicence RG2 experimental glioma nationallicence amsacrine nationallicence polymer implant nationallicence Wahlberg L. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut Almqvist P. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut Glantz M. Department of Clinical Neuroscience, Section of Neurology, Brown University School of Medicine, Providence, Rhode Island, USA aut Boëthius J. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut Acta Neurochirurgica Springer-Verlag 138/11(1996-11-01), 1323-1330 0001-6268 138:11<1323 1996 138 701 https://doi.org/10.1007/BF01411063 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01411063 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wahlberg L. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut NATIONALLICENCE 700 1- Almqvist P. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut NATIONALLICENCE 700 1- Glantz M. Department of Clinical Neuroscience, Section of Neurology, Brown University School of Medicine, Providence, Rhode Island, USA aut NATIONALLICENCE 700 1- Boëthius J. Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden aut NATIONALLICENCE 773 0- Acta Neurochirurgica Springer-Verlag 138/11(1996-11-01), 1323-1330 0001-6268 138:11<1323 1996 138 701 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer